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Background: Oxaliplatin based chemotherapy is often used as adjuvant therapy in colon and rectal cancer. A
reported side effect is Sinusoidal Obstruction Syndrome which is characterized by a spectrum of pathologic
changes, from sinusoidal dilation, peri-sinusoidal haemorrhage, peliosis and nodular regenerative hyperplasia.
Very rarely it can cause the development of liver nodules mimicking liver metastases. Herein, we report a case of
Sinusoidal Obstruction Syndrome causing a liver nodule suspicious of liver metastasis on imaging. This is the
third reported case of this complication of oxaliplatin toxicity, in which resection was performed and pathological
diagnosis confirmed.
Case presentation: We report the case of a 59 year old man with stage III colon cancer who underwent
sigmoidectomy followed by adjuvant chemotherapy with oxaliplatin. One year after surgery a liver nodule was
detected and the patient underwent right hepatectomy. Pathology showed no liver nodule and diagnosed
sinusoidal obstruction syndrome.
Conclusion: We describe the third reported case of a liver lesion mimicking a liver metastasis after oxaliplatin-based
chemotherapy for colon cancer. We suggest that in patients heavily treated with oxaliplatin with de novo liver nodules,
this differential diagnosis should be considered. In particular, in this population of patients an intense
imagiologic evaluation and even a preoperative biopsy should be pursued to confirm the diagnosis of
malignancy and avoid overtreatment.Background
Oxaliplatin based chemotherapy is often used as adju-
vant therapy in colon and rectal cancer or in periopera-
tive therapy in liver metastatic disease [1,2]. A reported
side effect is Sinusoidal Obstruction Syndrome (SOS),
formerly known as veno-occlusive disease, which is char-
acterized by a spectrum of pathologic changes, from
sinusoidal dilation, peri-sinusoidal haemorrhage, peliosis
and nodular regenerative hyperplasia [3]. SOS can cause
increased morbidity after liver resection [4] but a re-
cently reported side effect is the development of liver
nodules mimicking liver metastases [5,6].
Herein, we report a case of SOS causing a liver nodule
on imaging suspicious of liver metastasis. This is the* Correspondence: halexandrino123@gmail.com
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toxicity, in which resection was performed and patho-
logical diagnosis confirmed.Case presentation
The patient was a 59 year old man with a recent history
of rectal bleeding and change in bowel habits. The pa-
tient had previous medical history of dyslipidemia and
was not taking any medication. Family history was unre-
markable for neoplasms. Physical examination showed a
patient in good general status, and palpation of the ab-
domen and rectal examination were normal. Colonos-
copy showed a stenotic, ulcerated lesion at 20 cm of the
anal verge and biopsy revealed a moderately differenti-
ated adenocarcinoma. Laboratory investigations showed
normal CEA (1.9 ng/mL) and CA 19.9 (14 U/mL). Liver
function tests were normal, apart from slight elevation
(130 U/L) of gama-glutamyl transpeptidase [(GGT) nor-
mal < 55]. Computed Tomography (CT) of the chest,ntral. This is an Open Access article distributed under the terms of the Creative
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Figure 2 Contrast enhanced CT after 12 cycles of oxaliplatin-based
adjuvant chemotherapy showing a new liver nodule in segment 8,
in close proximity to the right hepatic vein (arrowhead).
Alexandrino et al. BMC Cancer  (2015) 15:247 Page 2 of 4abdomen and pelvis revealed no distant metastases
(Figure 1).
Sigmoidectomy was performed and the postoperative
period was complicated by anastomotic breakdown and
pelvic sepsis. Re-laparotomy, drainage and loop ileostomy
were performed but the postoperative course was other-
wise uneventful. Pathology showed a well differentiated
adenocarcinoma (T3N1bMx) of the rectum-sigmoid tran-
sition and the patient underwent 12 cycles of adjuvant
chemotherapy with capecitabine and oxaliplatin.
One year after surgery, a 28 mm hypodense liver
nodule on segment 8 was discovered on routine post-
operative CT (Figure 2); this nodule was not present
on preoperative CT. Blood levels of CEA and CA 19.9
remained normal (1.6 ng/mL and 11 U/mL respect-
ively). Liver function tests were unremarkable, with a
sustained elevation of GGT (143 U/L). A diagnosis of
liver metastasis was made and after discussion in our
multidisciplinary meeting a resection was proposed
(and accepted) to the patient.
During laparotomy, perioperative ultrasound confirmed
a 30 mm hyperechoic lesion in segment 8, not typical of
metastases, and no other liver lesions. A right hepatec-
tomy and closure of loop ileostomy were performed. Post-
operative period was uneventful and the patient was
discharged on the 6th postoperative day. No further treat-
ment was prescribed.
On gross examination the liver parenchyma had congest-
ive areas with no evidence of nodule. Histologically there
was haphazardly distributed sinusoidal congestion and
dilatation with variable intensity. In some areas sinusoidal
dilatation was intense with hemorrhage, trabecular atrophy,
focal peliosis and perisinuosoidal fibrosis and the hepatic
veins were normal. (Figures 3, 4, 5 and 6).Figure 1 Contrast enhanced abdominal preoperative staging
CT showing no liver nodules.One year after liver resection and two years after re-
section of the primary the patient is well, without clin-
ical, biological or radiological evidence of recurrence.
Discussion
Oxaliplatin based chemotherapy is commonly used in
the adjuvant setting in colorectal cancer and as conver-
sion or neoadjuvant therapy in colorectal cancer liver
metastases (CRCLM) [1,2]. A well-documented side ef-
fect is Sinusoidal Obstruction Syndrome (SOS), formerly
known as venoocclusive disease, a recognized complica-
tion of bone marrow transplantation; but also of chemo-
therapy with oxaliplatin [3,7].
Pathophysiology of SOS is still not completely under-
stood but is probably related to the development of aFigure 3 Panlobular diffuse sinusoidal dilatation and congestion
(H&E 40x).
Figure 4 Normal terminal hepatic veins (H&E 200x). Figure 6 Atrophic hepatocelular plates and perisinusoidal
fibrosis (Trichrome Masson 200x).
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plasminogen activator inhibitor 1 (PAI.1), vonWillen-
brand factor (vWF) and Matrix Metalloproteinases
(MMP’s) [8-10] The role of angiogenesis is probably
confirmed by the presence of sinusoidal capillarization
and the protective role of bevacizumab, an antiangio-
genic monoclonal antibody [3,11].
SOS is characterised by hepatic sinusoidal dilatation,
hepatocyte atrophy, peri-sinusoidal fibrosis, and nodular
regenerative hyperplasia. These histological changes ap-
pear to be present in up to 40% of patients treated with
oxaliplatin based regimens undergoing liver resection;
and by causing portal hypertension, they increase the
risk of perioperative bleeding and postoperative liver
failure [4,11,12].
Although SOS can cause nodular regenerative hyper-
plasia, the finding of a nodule mimicking liver metastasis
has been, to the author’s knowledge, only described in
the literature in two precedent publications. In the re-
port by Uchino et al. [5], multiple liver nodules wereFigure 5 Extreme sinusoidal dilatation with peliosis (H&E 100x).discovered after only six cycles of fluorouracil and oxali-
platin adjuvant chemotherapy. The nodules were all less
than 20 mm in size and all in the right liver. Magnetic
Resonance Imaging (MRI) showed hyperintense lesions
on T2-weighted images. There was however no restric-
tion to diffusion which, in retrospective and in the au-
thor’s opinion, would argue against metastases. During
operation resection of one of the nodules was performed
and frozen section pathological exam showed severe sinus-
oidal dilation. The remaining lesions were not resected and
regressed after stopping chemotherapy.
Xiong et al. [6] describe a single nodule detected as
hypodense lesion in segment 8, also not present in previ-
ous CT. MRI confirmed the lesion as hyperintense on
T2 and without enhancement after gadolinium constrast
administration. Diffusion-weighted imaging was not re-
ported in this case. The lesion presented metachronously
one year after surgery of the primary and after adjuvant
chemotherapy with capecitabine and oxaliplatin. There
was also no elevation in CEA or CA 19.9 levels. A pre-
sumptive diagnosis of CRCLM was made and hepatec-
tomy was performed. Pathology showed peliosis hepatis,
a lesion in the spectrum of SOS. However, there is no
pathological description of sinusoidal dilation.
In our case the nodule was detected 12 months after
surgery of the primary and 6 months after the end
of chemotherapy. There was no elevation in tumour
markers and the lesion was detected as a hypodense le-
sion with 28 mm in the right liver. Diffusion-weighted
MRI could have been done in order to investigate this
nodule, and is nowadays performed more frequently in
our centre. An alternate differential diagnosis would be
of a necrotic nodule but distinction from a CRCLM is
sometimes difficult [13]. Intraoperative ultrasound dis-
played a hyperechoic mass in segment 8, which is unusual
in colorectal liver metastases. Finally, in our patient the
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hepatic vein precluded frozen section examination or
minor hepatectomy and left us with no option but perform-
ing right hepatectomy.
To our knowledge this is the third reported case of a
liver nodule developing after chemotherapy with oxali-
platin. We suggest that in patients treated with oxalipla-
tin with de novo liver nodules, this differential diagnosis
should be considered and further imaging evaluation
should be pursued. In particular, diffusion-weighted MRI
and PET-CT are important imaging techniques in the
management of patients with CRC [14]. The finding of
atypical radiologic features not suggestive of liver metas-
tases, such as no restriction to diffusion on MRI, should
prompt liver biopsy. Further studies however are needed,
in particular on the incidence of SOS, peliosis hepatis
and nodular regenerative hyperplasia and on the imaging
findings associated with it. We believe that further inves-
tigation is currently needed on the pathophysiology of
SOS [9,10].
In conclusion, we think this case should alert clinicians
treating colorectal cancer patients to a rare but poten-
tially severe complication of oxaliplatin; it can be re-
sponsible for a misdiagnosis of liver metastases and for
overtreatment of the patients. However, we also caution
to the fact that most liver nodules detected during
follow-up for colorectal cancer are indeed liver metasta-
ses and any decision for resection should be taken in
high-volume hepatobiliary centres, after thorough dis-
cussion in a multidisciplinary setting.
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